Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes

• New data shows that Amarin Corporation plc's (NASDAQ: AMRN) Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors.

• The REDUCE-IT study data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo.

• IPE also significantly reduced NSTEMI by 27%.

• Related: Amarin Still Suspends FY22 Guidance On Generic Challenges.

• "This analysis of REDUCE-IT clearly shows that IPE 4 g/day as an adjunct to statin therapy in high-risk patients with residual hypertriglyceridemia provides a large and significant reduction in heart attacks," said Deepak Bhatt, principal investigator of the REDUCE-IT trial.

• In time to first event analyses, MI was significantly reduced with IPE treatment, with a number needed to treat (NNT) of 39.

• There were clinically meaningful and statistically significant reductions in MI subtypes, including MI leading to cardiac arrest and resuscitated MI.

• IPE also significantly reduced the overall burden of total (first and subsequent) STEMI and total NSTEMI versus placebo.

• Price Action: AMRN shares are down 0.38% at $1.29 on the last check Friday.

See more from Benzinga

• Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know

• 89bio's Pegozafermin Data Shows Improved Liver Fat, Glycemic Control

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.